Clinical Trial: Prospective Study to Evaluate the Clinical Utility of ctDNA Tumor Fraction (TF) for Detection of ESR1 Mutations in HR+/HER2- Metastatic Breast Cancer (MBC)

U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07910565) titled 'Prospective Study to Evaluate the Clinical Utility of ctDNA Tumor Fraction (TF) for Detection of ESR1 Mutations in HR+/HER2- Metastatic Breast Cancer (MBC)' on Oct. 26.

Brief Summary: This is a prospective, single center, single-arm interventional study to evaluate the clinical utility of protocol-mandated diagnostic testing algorithm incorporating liquid biopsy and reflex tissue biopsy NGS for detection of ESR1 mutations in HR+/HER- metastatic breast cancer.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Breast Cancer Metastatic Breast Cancer HR+/HER- Metastatic Breast Cancer

Intervention: DIAGNOSTIC_TEST: ...